ADUHELM is indicated for the treatment of Alzheimer’s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).

Support for patients currently on ADUHELM

Biogen has discontinued the commercialization and development of ADUHELM.

Patients currently prescribed and taking ADUHELM are eligible for continued dosing until November 1, 2024.*

ADUHELM will no longer be available for purchase after November 1, 2024. Please contact Biogen Medical Information at 1-866-633-4636 if you have any questions regarding this withdrawal.

*Patient out-of-pocket cost may vary based on financial and other income considerations. This program only covers the cost of ADUHELM. Other services or fees associated with treatment are not included and patients may have out-of-pocket costs associated with the same. Other restrictions apply. Biogen reserves the right to modify or discontinue this program with respect to any patient, or in its entirety, at any time. Patients currently enrolled in the Free Drug program, who are currently enrolled in the PATH program, who have already applied for enrollment in the PATH program, or who purchase ADUHELM outside of these programs will continue to have access through November 1, 2024. Patients' last infusion date must be on or before November 1, 2024. After January 31, 2024 no new patient applications were accepted for review in the PATH program. Contact Biogen Support Services for Patients for full program details and Terms and Conditions.

Return Policy

Effective immediately, customers may return any surplus commercial units of unused ADUHELM, regardless of the expiration date, via the standard return process. For the avoidance of doubt, any Free Goods that are currently at the customer site should be disposed of by the customer directly. Biogen will accept all ADUHELM returns through 12/31/24.

For wholesalers ONLY: Per Biogen’s Return Good Policy, credit will be issued at Wholesale Acquisition Cost at the time of Product’s shipment from Biogen, less discounts within 30 days of the Returns vendor receiving the return.

If you have any questions about this process, or to inquire about whether ADUHELM is eligible for a return, please email:

Patient Registry

The Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) is a voluntary provider-enrolled patient registry that collects information on treatments for Alzheimer’s disease, including ADUHELM. Providers may obtain information about the registry at or contact